Opexa Therapeutics Reports Third Quarter 2013 Financial Results and Provides Corporate Update
Published: Nov 08, 2013
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today reported financial results for the third quarter ended September 30, 2013 and provided an overview of the Company’s recent corporate developments.
Help employers find you! Check out all the jobs and post your resume.